Occidiofungin's chemical stability and in vitro potency against Candida species

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 765-769

  Ellis, Dayna ^a   Gosai, Jiten ^a   Emrick, Charles ^a   Heintz, Rachel ^a   Romans, Lanette ^a   Gordon, Donna ^a   Lu, Shi En ^b   Austin, Frank ^c   Smith, Leif ^d  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

^c MISSISSIPPI STATE UNIVERSITY   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPEPTIDE;

ARTICLE; BURKHOLDERIA; CANDIDA; FUNGICIDAL ACTIVITY; IN VITRO STUDY; NONHUMAN; PH; PRIORITY JOURNAL; TEMPERATURE; YEAST;

ANTIFUNGAL AGENTS; BURKHOLDERIA; CANDIDA; CANDIDA ALBICANS; HUMANS; HYDROGEN-ION CONCENTRATION; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PEPTIDE HYDROLASES; TEMPERATURE;

EID: 84863393806     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05231-11     Document Type: Article

References (30)

1. Charlier C, et al. 2006. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother. 57:384-410. (Pubitemid 43240191)
2. Clancy CJ, Huang H, Cheng S, Derendorf H, Nguyen MH. 2006. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob. Agents Chemother. 50:2569-2572. (Pubitemid 43993208)
3. Cota J, et al. 2006. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob. Agents Chemother. 50:3926-3928. (Pubitemid 44684919)
4. Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. (Pubitemid 37222342)
5. Douglas CM, et al. 1994. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-Dglucan synthase. Proc. Natl. Acad. Sci. U. S. A. 91:12907-12911.
6. Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA. 1999. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis. 33:75-80. (Pubitemid 29115034)
7. Ernst EJ, Klepser ME, Pfaller MA. 2000. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:1108-1111. (Pubitemid 30165304)
8. Espinel-Ingroff A. 2008. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev. Iberoam. Micol. 25:101-106. (Pubitemid 351798337)
9. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
10. Ghannoum MG, Rice LB. 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin. Microbiol. Rev. 12:501-517. (Pubitemid 29484744)
11. Gu G, Smith L, Liu A, Lu SE. 2011. Genetic and biochemical map for the biosynthesis of occidiofungin, an antifungal produced by Burkholderia contaminans strain MS14. Appl. Environ. Microbiol. 77:6189-6198.
12. Gu G, Smith L, Wang N, Wang H, Lu SE. 2009. Biosynthesis of an antifungal oligopeptide in Burkholderia contaminans strain MS14. Biochem. Biophys. Res. Commun. 380:328-332.
13. Gu G, Wang N, Chaney N, Smith L, Lu SE. 2009. AmbR1 is a key transcriptional regulator for production of antifungal activity of Burkholderia contaminans strain MS14. FEMS Microbiol. Lett. 297:54-60.
14. Ha Y-S, Covert SF, Momany M. 2006. FsFKS1, the 1,3-beta-glucan synthase from the caspofungin-resistant fungus Fusarium solani. Eukaryot. Cell 5:1036-1042. (Pubitemid 44100702)
15. Hashimoto S. 2009. Micafungin: a sulfated echinocandin. J. Antibiot. 62:27-35.
16. Ikeda F, et al. 2007. Role of micafungin in the antifungal armamentarium. Curr. Med. Chem. 14:1263-1275. (Pubitemid 46739326)
17. Kanasaki R, et al. 2006. FR220897 and FR220899, novel antifungal lipopeptides from Coleophoma empetri no. 14573. J. Antibiot. 59:149-157. (Pubitemid 43667145)
18. Kavanagh K. 2007. New insights in medical mycology.Springer, New York, NY.
19. Klepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212. (Pubitemid 28227921)
20. Klepser ME, et al. 2001. Multi-center evaluation of antifungal time-kill methods. J. Infect. Dis. Pharmacother. 5:29-41. (Pubitemid 34101360)
21. Lee CH, et al. 1994. Cepacidine A, a novel antifungal antibiotic produced by Pseudomonas cepacia. I. Taxonomy, production, isolation and biological activity. J. Antibiot. (Tokyo) 47:1402-1405.
22. Li C, et al. 2001. Regional-dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs. J. Pharm. Sci. 90:47-57. (Pubitemid 32050476)
23. Lim Y, et al. 1994. Cepacidine A, a novel antifungal antibiotic produced by Pseudomonas cepacia II. Physico-chemical properties and structure elucidation. J. Antibiot. 47:1406-1416.
24. Lorian V. 2005. Antibiotics in laboratory medicine. Lippincott Williams & Wilkins, Philadelphia, PA.
25. Lu SE, et al. 2009. Occidiofungin, a unique antifungal glycopeptide produced by a strain of Burkholderia contaminans. Biochemistry 48:8312-8321.
26. Raasch RH. 2004. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev. Anti Infect. Ther. 2:499-508. (Pubitemid 39162361)
27. Radding JA, Heidler SA, Turner WW. 1998. Photoaffinity analog of the semisynthetic echinocandin LY303366: identification of echinocandin targets in Candida albicans. Antimicrob. Agents Chemother. 42:1187-1194. (Pubitemid 28227918)
28. Tawfik KA, et al. 2010. Burkholdines 1097 and 1229, potent antifungal peptides from Burkholderia ambifaria 2.2N. Org. Lett. 12:664-666.
29. Wiederhold NP, et al. 2007. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. 51:1616-1620. (Pubitemid 46744135)
30. Wu XC, et al. 2010. Isolation and partial characterization of antibiotics produced by Paenibacillus elgii B69. FEMS Microbiol. Lett. 310:32-38.